Syn­thet­ic DNA play­er Touch­light scores $60M round to more than triple man­u­fac­tur­ing ca­pac­i­ty as mR­NA gets hot

With the twin au­tho­riza­tions of Pfiz­er/BioN­Tech’s and Mod­er­na’s mR­NA vac­cines for Covid-19 late last year, the mar­ket for start­ing ma­te­ri­als for that type of shot has seen a big boost. One UK play­er with a new way to man­u­fac­ture DNA, a key pre­cur­sor to pro­duc­ing mR­NA, is cash­ing a siz­able check to scale up in a big way.

Touch­light has wran­gled $60 mil­lion in fi­nanc­ing to add 11 pro­duc­tion suites to its Lon­don site spe­cial­iz­ing in pro­duc­ing syn­thet­ic DNA it says can be pro­duced much faster than nor­mal plas­mid DNA, the com­pa­ny said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.